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Abstract
Background: Hypertension and chronic kidney disease (CKD) are common conditions and both are major risk
factors for cardiovascular events. The objectives were 1) to study the prevalence of CKD in hypertensive patients and 2)
to study the association of CKD with cardiac and vascular complications in a multicenter, nation-wide fashion.
Methods: This cross-sectional study evaluated patients aged 20 years or older who were diagnosed with hypertension
and who had been treated for at least 12 months at 831 public hospitals in Thailand during the 2012 study
period. Outcome measurements included calculated glomerular filtration rate (GFR) and cardiac and vascular
complications that included coronary artery disease, stroke, peripheral arterial disease, heart failure, and atrial
fibrillation. Multivariable modeling was conducted to determine independent factors associated with increased
risk of cardiac and vascular complications.
Results: A total of 28770 patients were enrolled. Average age was 62.8 years and 37% were male. Prevalence of
CKD stage 3 and 4–5 was 33.2 and 4.3%, respectively. Prevalence of cardiac and vascular complications was 10.
5% (5% having coronary artery disease, 3.9% stroke, 1.7% heart failure, and 1.2% atrial fibrillation). CKD was an
independent risk factor associated with each of the complications and overall cardiac and vascular complications with
an adjusted Odds ratio of 1.4 for CKD stage 3 and 1.9 for CKD stage 4–5.
Conclusion: Prevalence of CKD stage 3–5 in hypertensive population was 37.5%. CKD is an independent risk factor for
adverse cardiac and vascular outcome.
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Background
Chronic kidney disease (CKD) is a leading cause of
morbidity and mortality among patients around the
world [1]. Prevalence of CKD has been estimated to be
8–16% worldwide [1]. Diabetes and hypertension are
major risk factors for the development of CKD [1, 2].
Hypertension doubles the risk of CKD in the general
population and the risk ratio has been reported to be as
high as 3.9 in older population [3]. Control of hyper-
tension can reduce the risk of developing CKD [2].
CKD is classified into 5 stages; CKD stages 1 and 2
have a glomerular filtration rate (GFR) of higher than
60 ml/min. The GFRs of CKD stages 3, 4 and 5 are 30–60,
15–30 and < 15 ml/min respectively [4]. Prevalence of the
different stages of CKD in Thailand was reported in 2
major studies namely the National Health Exam Survey
(NHES) [5] and the Thai Screening and Early Evaluation
of Kidney Disease (Thai SEEK) study [6]. The NHES study
involved 3117 subjects with the average age of 33.6 years;
22.5% of subjects had hypertension [5]. Prevalence of
CKD stages 3, 4, and 5 from the NHES studies was 8.1,
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0.2, and 0.15%, respectively. The Thai SEEK study enrolled
3459 subjects with mean age 46.2 years, 16.5% of patients
had a history of hypertension. The Thai SEEK study found
prevalence of CKD stages 1–2 and stage 3–4 of 8.9 and
8.6%, respectively [6]. However, there are limited data on
the prevalence of CKD in hypertensive population is Asian
countries.
Recent practice guidelines for cardiovascular prevention
regarded CKD as a major risk factor for cardiovascular
event [7]. CKD stages 4–5 increases risk of cardiovascular
event with an Odds ratio of 4–50 [8]. Even in patients
with cardiac disease, severity of CKD has been shown to
be a better predictor of cardiovascular events than left
ventricular ejection fraction [9, 10]. Prevalence of CKD
among patients admitted with acute myocardial infarction
was 30–42% [11]. Patient with CKD had an increased risk
of cardiovascular event 2–7 times higher than those with-
out CKD [8, 11]. There was little data on the association
of CKD and cardiovascular outcome in Asian population
[12]. It has been reported that patients with CKD are
normally more likely to receive treatment that does not
closely follow generally accepted practice guidelines than
treatment received by patients that do not have CKD [11].
The primary objective of this study was to determine
the association between CKD and cardiac and vascular
complications in hypertensive patients. The secondary
objectives were to: 1) study the prevalence of CKD in
hypertensive patients; and 2) study the prevalence of cardiac
and vascular complications in patients with hypertension.
Methods
Study population
This cross-sectional survey was conducted in Thailand
in 2012 to evaluate nation-wide standard of care and
treatment outcome among hypertensive patients who
were treated at public Thailand Ministry of Public Health
(MoPH) hospitals in Thailand and private clinics in
Bangkok that participate in the Thailand National Health
Security Office (NHSO)’s program. Patients were enrolled
if they were diagnosed with hypertension, aged 20 years or
older and received regular treatment in the participating
hospital or clinic for the past 12 months. All patients were
recruited from the ambulatory unit. We excluded patients
participating in clinical trials.
We used a two-stage stratified cluster, proportional to
the size sampling technique, to select a nationally and
provincially representative sample of patients who were
diagnosed as hypertension. In provinces outside of Bangkok,
participating hospitals included all public hospitals under
the oversight of the Thailand Ministry of Public Health
(MoPH). For Bangkok, targeted hospitals included all
hospitals and clinics that were participated in the Thailand
NHSO program. The sampling started at the first stage of
77 strata at the provincial level. The second stage was at
the hospital level in each province. In each province,
hospitals were stratified into 5 strata, according to sizes.
The largest size was more than 500 beds (regional
center hospital) followed by 200–500 beds (provincial
general hospital), 90–120 beds (large community hospital),
30–90 beds (medium community hospital), and 10–30 beds
(small community hospital). University hospitals were not
included from our study.
This study was approved by the Royal Thai Army
Medical Department Ethical Review Board, the Ethical
Review Committee for Research in Human Subjects,
Thailand Ministry of Public Health. The protocol for this
study was also approved by the Institutional Review
Boards of all participating hospitals. Written informed
consent was obtained from subjects prior to participation.
This study was supported by the Thai National Health
Security Office (NHSO).
Data collection process
A total of 831 hospitals under the Thai Universal Coverage
Scheme were included. The number of regional hospitals,
general hospitals and community hospitals were 25, 70, and
736 respectively. Every regional and general hospital was
included. Community hospitals were randomly sampled
with 70% of small-sized hospitals, 20% of medium-sized
hospitals and 10% of large-size community hospitals. These
proportions were based on the proportion of health care
provided at various hospitals levels. Patients diagnosed as
hypertension were randomly selected according to the pro-
portion that were registered at each hospital. Sample size of
the study was derived from the proportion to size model.
To minimize the selection bias, all patients who were
randomly selected was invited by the study nurse to
participate in this study. Data were retrieved from patient’
medical records, which included baseline characteris-
tics, presence of hypertensive complications, and
laboratory test results. The study nurse was trained for
the process of data collection. The required data were
retrieved from medical recorded and entered in the
case record form (CRF). Entry of data in the CRF was
based on data that were written in the medical record
or from the ICD-10 diagnostic code. This applied to
diagnosis of hypertension and all other diagnoses. A
majority of participating hospitals had medical record
in non-electronic format limiting the opportunity of
data transfer from hospital electronic database. The
case record form was then sent to the central data
management or MEDRESNET (Medical Research
Network). Data management officers at MEDRESNET
manually adjudicated the data and ensured that the
data in the case record form complied with the study
protocol. In case of doubt the query was sent to study
site to verify with the data in the medical record.
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Assessment of renal function
Glomerular filtration rate (GFR) was calculated by Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI)
formula [13, 14]. GFR was classified into 3 groups: ≥60 ml/
min; 30–59 ml/min (CKD stage 3); and, <30 ml/min (CKDs
stage 4 or 5).
Other measurements
The following variables were collected: demographic data;
height; weight; body mass index (BMI); cardiovascular risk
factors; systolic blood pressure (SBP); diastolic blood pres-
sure (DBP); blood chemistry, including fasting plasma
glucose (FPG), lipid profiles, serum creatinine, uric acid,
proteinuria from urine analysis; available ECG data and
results. The laboratory results were the most recent results
within 12 months prior to the consent process.
The data management team is responsible for inquiries
to study sites to verify data. By a random selection
process, site monitoring was performed in approximately
60 hospitals or 10% of study sites.
Primary outcome measurements were cardiac and
vascular complications, which included coronary artery dis-
ease (CAD), stroke, peripheral arterial disease (PAD), heart
failure, and atrial fibrillation. CAD was defined as angina
pectoris, myocardial infarction, or coronary revasculari-
zation. Stroke was defined as cerebral infarction, TIA,
unspecified stroke, or hemorrhagic stroke. Vascular com-
plication was defined as CAD, stroke, or PAD. Secondary
outcomes were defined as individual components of
cardiac and vascular complications.
Statistical analysis
Continuous data were presented as mean and standard
deviation and categorical variables were expressed as
number and percentage. Comparisons of continuous
data were performed by independent samples t-test.
Comparisons were performed by chi-square test for
categorical data. Continuous data were grouped for Odds
ratio analysis, as follows: age ≥ or < 65 years, SBP ≥ or <
140 mmHg, DBP ≥ or < 90 mmHg, TC ≥ or < 200 mg/dl,
TG ≥ or < 200 mg/dl, HDL < or ≥ 40 mg/dl, LDL ≥ or <
100 mg/dl, BMI ≥ or < 25 kg/m2, GFR < or ≥ 60 ml/min,
and uric acid ≥ or < 7 mg/dl in male and ≥ or < 6 mg/dl in
female. When missing data were detected during data
entry, query of raw data was sent to the study site for veri-
fication. During data analysis, since the number of patients
is large and number of missing data was small in the
majority of data as shown in Table 2 (meaning that bivari-
ate analysis represents an available case analysis). For the
multivariable models complete-cases analysis and multiple
imputation analysis were performed. We have now in-
cluded a forest plot in the results that indicates the effect
on missing data. This plot allows comparison between the
estimates and 95% CI from the complete cases and
imputed analysis.
Odds ratio and 95% confidence interval (CI) for uni-
variate analysis were determined by chi-square test.
Multivariate logistic regression analysis (with forward
LR) was used to determine the independent factors
that are associated with increased risk of cardiac and
vascular complications using complete-cases analysis
with and without imputation method for the missing
data. For imputation method, missing values were imputed
by using the means of complete cases with noise added
based on the t-distribution. CKD was tested to determine
whether or not it was an independent risk factor associated
with cardiac and vascular complications after adjustment
for other baseline characteristics. A p-value less than 0.05
was considered statistically significant. All statistical
analyses were performed using SPSS Statistics version
20 (SPSS, Inc., Chicago, IL, USA).
Results
There were a total of 28770 patients; with a mean age
62.8 ± 11.3 years; 10650 (37.0%) of our subjects were
male. Average GFR was 68.3 ± 22.8 ml/min; ≥60 ml/
min in 17970 (62.5%), 30–59 ml/min in 9553 (33.2%),
and <30 ml/min in 1247 patients (4.3%). Prevalence of
CKD stage 3 and stages 4–5 increased with age (Fig. 1)
but appeared to have no gender-related predisposition
(CKD stage 3 and stages 4–5 were 35.3 and 4.3% in
men and 32.0% and 4.4% in women). Prevalence of
cardiac and vascular complications is shown in Table 1.
Overall prevalence was 10.5% with CAD being the most
prevalent condition followed by stroke. Cardiac and
vascular complications increased with age and men
more than women (Fig. 2). Prevalence of all cardiac and
vascular complications appears to increase as the level
of GFR declined (Fig. 3).
Baseline characteristics, blood chemistry data, control
status of cardiovascular risk factors and prevalence of
cardiac and vascular complications in each group are
shown in Table 2. Hypertension was well controlled
(SBP <140 and DBP <90 mmHg) in 78.0%. FPG was in
good control (<100 mg/dL) in 47.8% and control for
LDL-cholesterol was good (<100 mg/dl) in 34.9%. The
univariate analysis indicates that increased age, male
gender, current smoking, general hospital, low BMI, high
SBP, low FPG, low total cholesterol, low triglyceride,
high HDL-cholesterol, low LDL-cholesterol, and low
levels of GFR are associated with cardiac and vascular
complications (all p < 0.05). Odds ratios and a forest plot
indicating the association of each of the baseline charac-
teristics with cardiac and vascular complications are
shown in Fig. 4. When the selected factors from univari-
ate analysis are mutually adjusted in the multivariable
modelling, higher age, male gender, general hospital, low
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total cholesterol, low triglyceride, high HDL-cholesterol,
low LDL-cholesterol, and low levels of GFR are identified
as independently associated with cardiac and vascular com-
plications (all p < 0.05). Crude and adjusted Odds ratio of
factors that were independently associated with cardiac and
vascular complications is shown in Table 3. Forest plot of
complete-cases analysis and imputation method is shown
in Fig. 5. The direction and significance of the individual
effects remains largely unchanged.
Data on proteinuria was available in only 2281 patients
(7.9%). Among patients who had available urine protein
data, the results were negative or trace in 874 (38.3%), 1+
in 768 (33.7%), 2+ in 447 (19.6%), 3+ in 159 (7.0%), and 4+
in 33 (1.4%). Since the number of patients with available
urine protein data was relatively small, we did not intend
to run the primary outcome analysis for proteinuria.
However, among patients with urine protein data,
proteinuria had an Odds ratio for the association with
cardiac and vascular complication of 1.20 (95% CI
0.92–1.58). The numerical association of proteinuria
and cardiac and vascular complication was mainly for
patients with CKD with the Odds ratio of 1.23 (95% CI
0.84–1.1.80) compared to those without CKD (Odds
ratio 1.00, 95% CI 0.67–1.49).
Multivariable adjusted Odds ratio and 95% CI for associ-
ation of levels of GFR with each factor of cardiac and vas-
cular complication are shown in Fig. 6. Results of the
analysis showed that the prevalence of each factor of
cardiac and vascular complication increased as the level of
GFR declined. Multivariable adjusted Odds ratio showed
that the level of association between levels of GFR and
each of cardiac and vascular complication remained the
same with the exception of atrial fibrillation.
Discussion
The results of this study demonstrated prevalence of CKD
stage 3 and 4–5 in patients with hypertension to be 33.2
and 4.3%, respectively. A decline in GFR in patients with
hypertension was independently associated with cardiac
and vascular complications which included CAD, stroke,
PAD, and heart failure.
Prevalence of CKD has increased over the past
20 years [1] as a result of greater proportion of older
people in the population and a corresponding increase
in the prevalence of cardiovascular risk factors, such as
diabetes and hypertension [1]. Uncontrolled hyperten-
sion is a major risk factor for CKD and patients with
CKD have an increased risk of hypertension not only
from related stiffening of arteries, but also related to
volume overload. A world-wide study showed that the
prevalence of CKD significantly increases in patients at
high risk for cardiovascular disease such as hyperten-
sion [15]. Prevalence of left ventricular hypertrophy
was as high as 50% in patients with GFR less than
30 ml/min [16]. Treatment of hypertension is very
effective in the prevention of CKD in patients with
hypertension [17]. Blood pressure target in patients
Fig. 1 Prevalence of CKD by age groups
Table 1 Prevalence of cardiac and vascular complications
Cardiac and vascular complications Number (%)
(Total N = 28770)
Coronary artery disease 1442 (5.0)
Stroke 1118 (3.9)
Peripheral arterial disease 29 (0.1)
All vascular disease 2499 (8.7)
Heart failure 487 (1.7)
Atrial fibrillation 346 (1.2)
All cardiac and vascular complications 3031 (10.5)
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with CKD has been proposed to be more stringent
than in patients without CKD [18].
Our study showed prevalence of CKD stage 3 and
stages 4–5 in patients with hypertension of 33.2 and
4.3% respectively. Mean age in our study population was
62.8 years. Previous study in healthy Thai individuals
from the NHES study showed prevalence of CKD stage
3 and stages 4–5 of 8.1 and 0.35%, respectively [5]. Data
from the Thai SEEK study reported prevalence of CKD
stages 3 and 4 of 7.5 and 1.1%, respectively [6]. The dif-
ference between our study and other studies mentioned
here is mainly the health status of the study population.
We studied patients with hypertension while previous
studies focused on healthy populations. Prevalence of
CKD stage 3–5 in patients with hypertension was reported
to be approximately 23% [19]. However, our estimate of
the prevalence of CKD in the hypertensive population was
considerably higher. Although previous studies and our
study enrolled patients from primary care centers, the
hospitals involved in our study included larger ‘regional
hospitals’. This difference may have partly influenced the
difference in CKD prevalence between our study and
previous studies, with a slightly higher mean age of our
study population also potentially playing a role.
Patients with CKD stage 3B or 4 (GFR 30–44 and
15–29 ml/min, respectively) had a decreased life expectancy
of 17 and 25 years, respectively [20] in comparison with a
decrease in life expectancy of 8 years in diabetes [21] and
3 years for hypertension [22]. CKD has recently been iden-
tified as a major risk factor for cardiovascular events [7, 8].
Fig. 2 Prevalence of vascular and cardiac complications in men and women by age groups
Fig. 3 Prevalence of each type of vascular and cardiac complication by GFR groups
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CKD and even proteinuria greatly increase cardiovascular
risk and are considered the highest risk group for cardio-
vascular disease [2] and cardiovascular disease is the major
cause of deaths in patients with CKD [23]. A study from
Taiwan reported that cardiovascular disease accounted for
71% of deaths in patients with CKD, as compared to 22% in
patients with normal kidney function [24]. We demon-
strated that CKD in patients with hypertension associated
with a substantially increased risk of cardiac and vascular
complications including CAD, stroke, PAD, heart failure
Table 2 Patient baseline characteristics and prevalence of cardiac and vascular complications (total N = 28770)
Baseline variables n Mean ± SD/number (%) Prevalence of cardiac and vascular complications (%)
Age (years) 28770 62.8 ± 11.3
Gender 28770
Male 10650 (37.0) 13.8
Female 18120 (63.0) 8.6
Current smoker 28770
Yes 2322 (8.1) 14.7
No 26448 (91.9) 10.2
Type of hospital 27662
General 9023 (32.6) 13.8
Community 18639 (67.4) 9.0
SBP (mmHg) 28758 131.1 ± 15.4
≥ 140 5814 (20.2) 11.4
< 140 22914 (79.8) 10.3
DBP (mmHg) 28754 75.8 ± 10.5
≥ 90 1690 (5.9) 10.7
< 90 27066 (94.1) 10.5
FPG (mg/dL) 25077 107.3 ± 31.0
≥ 100 13088 (52.2) 10.0
< 100 11989 (47.8) 10.9
TC (mg/dL) 25228 193.8 ± 43.3
≥ 200 10263 (40.7) 7.9
< 200 14965 (59.3) 11.9
TG (mg/dL) 26502 154.5 ± 86.8
≥ 200 5477 (20.7) 8.6
< 200 21025 (79.3) 10.6
HDL (mg/dL) 23933 48.8 ± 13.7
≥ 40 6060 (25.3) 11.8
< 40 17873 (74.7) 9.7
LDL (mg/dL) 25586 115.9 ± 36.4
≥ 100 16653 (65.1) 8.6
< 100 8933 (34.9) 13.1
GFR (ml/min) 28770 68.3 ± 22.8
≥ 60 17970 (62.5) 8.7
30–59 9553 (33.2) 13.3
< 30 1247 (4.3) 16.2
Uric acid (mg/dL) 9563 6.1 ± 1.6
High 3890 (40.7) 10.5
Normal 5673 (59.3) 10.1
SD Standard deviation, DM Diabetes mellitus, SBP Systolic blood pressure, DBP Diastolic blood pressure, TC Total cholesterol, TG Triglyceride, HDL High density
lipoprotein cholesterol, LDL Low density lipoprotein cholesterol, GFR Glomerular filtration rate by epidemiology collaboration formula
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and atrial fibrillation. The adjusted Odds ratio was 1.4 in
patients with GFR 30–59 ml/min and 1.7 for those with
GFR below 30 ml/min, in comparison to those with GFR
above 60 ml/min. This information is meaningful not only
for specialists but also for primary care physicians [25]. We
cannot make conclusion on the significance of proteinuria
since the proteinuria data was relatively small. However,
our data showed increased risk of cardiac and vascular
complication of proteinuria in patients with CKD.
Many mechanisms facilitate and contribute to increased
cardiovascular risk in CKD. Patients with CKD were com-
monly found to have concomitant cardiovascular risk
factors, such as diabetes and hypertension. Patients with
CKD had increased activation of renin-angiotensin and
sympathetic response compared to those with normal
renal function [8, 26]. Moreover, patients with CKD had
higher levels of inflammatory biomarkers [27] and endo-
thelial dysfunction [28]. In addition to increased risk of
cardiovascular disease, patients with CKD, both with and
without documented vascular disease, usually received
treatment that was less than the treatment practice guide-
lines, as compared to patients without CKD [11].
Recent report shows a high prevalence of CKD in
hypertensive patients and a strong association of CKD
and cardiac and vascular complication [15]. This study
also shows that more than half of patients with CKD are
unaware of this condition. Therefore, these patients have
limited opportunity to obtain advice on self-care to slow
the progression of CKD and minimize the risk of com-
plications. Registry data from several Asian countries
show that a large proportion of CKD patients have a
poor control of risk factors especially in those with
diabetes [29].
Our study had some limitations. This was a cross-
sectional study. We did not collect medication data such
as anti-hypertensive medications, anti-thrombotic medi-
cations, and statins. The nature of our study design
cannot prove cause and effect of identified associations.
This study was designed for a cross-sectional survey and
did not plan for a collection of follow-up data. Therefore
Fig. 4 Bivariate analysis factors affecting cardiac and vascular complications (shown as Odds ratio, 95% CI, and forest plot) (*GFR was analyzed by
using group with GFR ≥ 60 ml/min as the reference)
Table 3 Crude and adjusted Odds ratio of factors that were independently associated with cardiac and vascular complications
Variables Crude OR (95% CI) p-value Multivariable adjusted OR (95% CI) p-value
Age ≥65 years 2.13 (1.97–2.30) <0.001 1.65 (1.48–1.83) <0.001
Men 1.70 (1.58–1.83) <0.001 1.62 (1.46–1.80) <0.001
General hospital 1.62 (1.50–1.75) <0.001 1.52 (1.37–1.68) <0.001
TC ≥200 mg/dL 0.63 (0.58–0.69) <0.001 0.82 (0.73–0.94) 0.003
TG ≥200 mg/dL 0.80 (0.72–0.88) <0.001 0.86 (0.75–0.98) 0.023
HDL ≥40 mg/dL 1.24 (1.13–1.36) <0.001 1.12 (1.00–1.26) 0.045
LDL ≥100 mg/dL 0.62 (0.58–0.68) <0.001 0.75 (0.66–0.84) <0.001
GFR ≥60 ml/min reference <0.001 reference <0.001
30–59 ml/min 1.62 (1.50–1.76) 1.39 (1.24–1.55)
< 30 ml/min 2.04 (1.74–2.39) 1.86 (1.50–2.31)
See abbreviation lists in Table 2
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we did not collect short or long-term outcome or
changes in GFR or proteinuria. In fact, the main purpose
of the main study was to determine the rate of blood
pressure goal achievement and to feedback to the par-
ticipating hospitals how good they are for blood pressure
control. This study collected data from hospital based
samples which may over-estimate the prevalence ob-
tained from community based individuals. All patients
were recruited from the ambulatory setting. Therefore
the probability of recruiting acute kidney injury (AKI)
cases should be very low since AKI cases should be ad-
mitted and managed in hospital setting. However, un-
detected AKI may be missed. The associations between
cardiac and vascular complications with low cholesterol,
low LDL-cholesterol, low triglyceride, and high HDL-
cholesterol could be due to the effect of statin use,
which would be more commonly found in patients with
cardiac and vascular disease. This could make some re-
sults of our study difficult to interpret. Methods of cre-
atinine measurement were not the same across all
participating centers. Approximately half of the centers
used enzymatic method for the measurement of serum
creatinine and another half used modified Jaffe method.
Enzymatic method was IDMS (isotope dilution-mass
spectrometry)-traceable. Although the method that was
used in many centers were not IDMS-traceable but all
centers had their own laboratory standard quality con-
trol system that applied to local practice. Lastly, there
Fig. 5 Forest plot shows Odds ratio and 95% CI of multivariate analysis of factors affecting cardiac and vascular complications from complete
case analysis and imputation method (*GFR was analyzed by using group with GFR ≥ 60 ml/min as the reference)
Fig. 6 Multivariable relationships between GFR groups and each type of cardiac and vascular complication
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were some cases with missing data, since it was not
mandatory to have every variable entered into the case
record form.
Conclusion
In conclusion, prevalence of CKD in our hypertensive
population was 37.5%. CKD is an independent risk factor
that is associated with many cardiac and vascular com-
plications. Improved awareness regarding detection and
management of CKD is very important, especially for
primary care physicians.
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